Grifols takes its plasma to the Murcia Health Service for €3 million

The Spanish pharmaceutical giant, Grifols,  which specializes in the production of plasma derivatives, has been awarded a contract by the Government of Murcia to supply plasma to centers dependent on the health service for $3.65 million (€3 million), according to a contract signed by the management of the Murcia Health Service and the pharma group. 

The Grífols family company will supply plasma to the Regional Center for Hemodonation of the Region of Murcia (CRH) for a period of 24 months. The object of the contract includes the collection of human plasma from the center, its transport to the facilities of the company awarded the contract, the conservation of the collected plasma, its conservation prior to fractionation, the temporary storage of the plasma derivatives obtained, as well as the distribution or making available of these plasma derivatives to the health facility. 

The CRH began its activity in June 1991, under the agreement signed between the Ministry of Health and Consumer Affairs and the Murcia Regional Ministry of Health. Previously, by order of April 4th of the same year, for a better use of the sanitary resources, the Health Department of Murcia configured the hematology and hemotherapy unit, by which the medical staff of the CRH and the hematology and hemotherapy service of the General University Hospital were integrated in the same unit.  

Read more about the company Grifols and find more financial news with our companion app, Born2Invest.

Grifols will distribute more than 51,400 vials of human albumin to the Murcia health system

Since it opened, the HRC has been responsible for supplying the hemotherapy needs of the autonomous community. Likewise, this center initiated and developed the hematopoietic progenitor transplant program in the region and actively collaborates in the registration of bone marrow donors. Under the contract, Grifols will distribute more than 51,400 vials of human albumin. This is a sterile solution of serum albumin, obtained by fractionation according to the Cohn method with cold ethanol, from a pool of venous blood plasma. The price for this fractionation is more than $705,000 (€580,000). 

The pharmaceutical company will also distribute more than 18,900 vials of immunoglobulin. These are antibodies in the blood, which can provide doctors with important information about the immune system. The cost for this is over $1.8 million (€1.5 million).  

Grifols takes its plasma to the Murcia Health Service for three million euros

Image of the Spanish pharmaceutical company Grifols closes this contract after announcing at the end of November an agreement with the Egyptian Government to develop the plasma medicine market in the country and to promote itself-supply. 

Through the constitution of a joint venture, in which the National Service Projects Organization (Nspo) holds 51% and Grifols 49%, the two companies will combine their industrial experience and financial efforts to develop, build and operate twenty plasma donation centers (with an initial capacity to obtain 600,000 liters of plasma per year) and production facilities. Grifols earned 486 million euros through September 2020, 14.7% more than in the first nine months of 2019, according to the latest available data. Revenue increased by 7.8% to $4.9 million (€4,03 million), according to the latest available results.

__

(Featured image by AhmadArdity via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.